In Ob/Ob and lipoatrophic mice, elevated expression of PPARγ2 is associated with non-alcoholic fatty liver disease (NAFLD) while inhibition of PPARγ expression reduces hepatic steatosis through downregulation of lipogenesis and inhibition of LD formation [38–40]. Here, PPARG is linked to fatty liver disease.